Atlas Trials

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Clinical trial NCT05048901 · RECRUITING

Trial details

NCT number
NCT05048901
Sponsor
National Health Research Institutes, Taiwan
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Neuroendocrine Tumors,Gastroenteropancreatic
Start date
2021-09-17
Primary completion
2027-08-31
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.